非布司他何时上市呢？

When will Febuxostat be launched? In April 2008, febuxostat (febuxostat, feburic) was approved for marketing in Europe. In February 2009, the FDA approved febuxostat (febuxostat, feburic) for marketing. On June 26, 2013, febuxostat was officially launched in China.

Febuxostat (febuxostat, feburic) is suitable for the long-term treatment of hyperuricemia combined with gout, including gout patients with increased uric acid production and decreased renal clearance. It is especially suitable for gout patients who are intolerant or contraindicated by allopurinol and whose uric acid cannot reach the target after allopurinol treatment. However, febuxostat (febuxostat, feburic) is not recommended for the treatment of asymptomatic hyperuricemia.

The starting dose of febuxostat (febuxostat, feburic) is 40 mg/d. After taking this dose for 2 weeks, monitor the blood uric acid level. If the blood uric acid does not reach the standard, increase the dose to 80 mg/d. The usual dose is 40~120 mg/d. The efficacy of febuxostat (febuxostat, feburic) 40 mg/d is equivalent to that of allopurinol 300 mg/d. Gout patients with mild to moderate renal insufficiency and mild hepatic insufficiency do not need to change the dosage of febuxostat, but they also need to regularly monitor changes in liver and kidney indicators.

The recommended usage of febuxostat (febuxostat, feburic) is oral administration once a day. Taking the medication is not affected by food and gastric acid, and does not affect its acid-lowering effect, so it can be taken at any time during the day. The correct understanding of this paragraph should be: febuxostat can be taken before or after meals, and it will not affect the efficacy of febuxostat; the type of food will not affect the efficacy of febuxostat. Gout patients can even take febuxostat with milk. But this does not mean that gout patients can relax their control on a high-purine diet after taking febuxostat.